|Bid||198.00 x 800|
|Ask||201.11 x 900|
|Day's Range||196.88 - 202.32|
|52 Week Range||83.37 - 203.64|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||205.71|
Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right stock, you can make a...
Fueling Discovery in Preserved Tissue Samples to Advance Clinical Translational ResearchPLEASANTON, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today announced it is shipping its new Visium Spatial Gene Expression for FFPE (formalin-fixed and paraffin-embedded) assay. The offering gives researchers access to the whole transcriptome across their entire tissue, enabling true unbiased discovery in FFPE samples for the first time. The product addresses customer demand
10x Genomics (NASDAQ: TXG), which is focused on helping researchers study genomic changes on a cellular level, beat Wall Street expectations in the first quarter, but shares of the company fell substantially. In this video from Motley Fool Live, recorded on May 10, Fool.com contributors Brian Orelli and Keith Speights discuss why the share price dropped and why the short-term move shouldn't affect long-term investors. Brian Orelli: Not every company had an impressive first quarter.